One of the losers of today's trading session was Elevance Health. Shares of the Medical specialities company plunged -2.7%, and some investors may be wondering if its price of $466.68 would make a good entry point. Here's what you should know if you are considering this investment:
-
Elevance Health has moved -4.4% over the last year, and the S&P 500 logged a change of 22.5%
-
ELV has an average analyst rating of buy and is -17.18% away from its mean target price of $563.5 per share
-
Its trailing earnings per share (EPS) is $25.72
-
Elevance Health has a trailing 12 month Price to Earnings (P/E) ratio of 18.1 while the S&P 500 average is 15.97
-
Its forward earnings per share (EPS) is $37.09 and its forward P/E ratio is 12.6
-
The company has a Price to Book (P/B) ratio of 2.85 in contrast to the S&P 500's average ratio of 2.95
-
Elevance Health is part of the Health Care sector, which has an average P/E ratio of 30.21 and an average P/B of 4.08
-
ELV has reported YOY quarterly earnings growth of -17.7% and gross profit margins of 0.3%
-
The company has a free cash flow of $6.04 Billion, which refers to the total sum of all its inflows and outflows of cash over the last quarter
-
Elevance Health, Inc. operates as a health benefits company. The company operates through four segments: Commercial & Specialty Business, Government Business, CarelonRx, and Other. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was founded in 1944 and is based in Indianapolis, Indiana.
